An update from BCAL Diagnostics Limited ( (AU:BDX) ) is now available.
BCAL Diagnostics Limited reported a significant decrease in revenue by 26% and an increased net loss of 66% for the half-year ending December 31, 2024, compared to the previous year. Despite the financial challenges, the company expanded its operations by incorporating a wholly owned subsidiary in North Carolina, USA, indicating a strategic move to enhance its market presence.
More about BCAL Diagnostics Limited
BCAL Diagnostics Limited operates in the medical diagnostics industry, focusing on developing innovative diagnostic solutions. The company is involved in creating technologies for early disease detection, with a market focus on improving healthcare outcomes.
YTD Price Performance: 10.0%
Average Trading Volume: 312,083
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: A$40.26M
Learn more about BDX stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com